Recently, the General Office of the People's Government of Beijing Municipality and the China Soong Ching Ling Foundation sent letters of appreciation, expressing their sincere gratitude to JumpCan Pharmaceutical for its support and assistance in ensuring medicine supply, and their sincere respect for the company's sense of responsibility and commitment to prioritizing the health needs of the people.
Since the easing of pandemic restrictions, JumpCan Pharmaceutical has actively responded to and implemented national and local epidemic prevention and control requirements, fulfilling its corporate social responsibility with high-quality medicines and services. In its letter, the General Office of the People's Government of Beijing Municipality thanked JumpCan Pharmaceutical for prioritizing the health needs of the people, resolutely implementing the requirements of the Medical Supplies Support Unit of the State Council's Inter-Agency Task Force, fully leveraging the advantages of its pharmaceutical industry chain, working overtime to increase production, and providing a high-quality and high-level emergency supply of Xiao'er Chiqiao Qingre Granules, which offered strong support for Beijing's medicine supply guarantee work.
The China Soong Ching Ling Foundation expressed its gratitude to JumpCan Pharmaceutical for promptly coordinating quality resources and helping the Foundation solve practical difficulties such as the shortage of emergency medicines with the most sincere dedication and highest efficiency. Prior to this, our company also collaborated with Party and government departments in multiple regions to distribute free health care packages containing approved pharmaceutical and disinfectant products, which received positive feedback from various parties.
Facing the overarching priorities of controlling the pandemic, stabilizing the economy, and ensuring secure development, JumpCan Pharmaceutical will continue to uphold its corporate mission of " Using Technology to Defend Health", adhere to "driven by innovation, embracing transformation", and find continuous resilience and vitality for performance growth and corporate development. We strive to make R&D more competitive, marketing more effective, production more creative, talent more cohesive, and our brand more influential. We aim to cultivate the company's first-mover advantages and potential, properly plan and achieve strategic objectives and operational targets, and are committed to become a leading, comprehensive pharmaceutical group trusted by patients in China.
